Results 81 to 90 of about 129,195 (289)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. [PDF]

, 2017
Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase and a molecule of adaptor that we have shown is important for non-small-cell lung cancer (NSCLC). We investigated if MET is a target of CBL and if enhanced in CBL-altered NSCLC.
Batra, Surinder K, Husain, Aliya N, Mirzapoiazova, Tamara, Salgia, Ravi, Sharma, Sherven, Srivastava, Minu K, Tan, Yi-Hung Carol, Vokes, Everett E, Won, Brian M, Zhu, Li   +9 more
core   +1 more source

Liquid Metal Nanotransformers for Drug‐Resistant Pan‐Cancer Therapy in Patient‐Derived Organoids

Advanced Science, EarlyView.
Pan‐cancer therapies are severely limited in drug‐resistance patients due to genetic mutations and other factors, resulting in poor therapeutic outcomes and constrained clinical benefit. Liquid metal nanotransformers, a new class of shape‐transformable nanomaterials capable of dramatic morphological changes, offer a promising physical strategy to ...
Xiaojie Yuan, Xuelin Wang, Zhongyao Chen, Shuo Wang, Weining Gao, Ziyi Chen, Runyang Li, Cheng Hao, Lei Zhang, Qiongqiong Zhang, Ke Zhang, Mei Yu, Qian Liu, Jingxuan Wang, Huiping Li, Simpkins Fiona, Jing Liu, Qiang Liu, Peng Liu, Yawei Hu   +19 more
wiley   +1 more source

Carboplatin binding to a model protein in non-NaCl conditions to eliminate partial conversion to cisplatin, and the use of different criteria to choose the resolution limit

, 2013
Hen egg white lysozyme (HEWL) co-crystallisation conditions of carboplatin without sodium chloride (NaCl) have been utilised to eliminate partial conversion of carboplatin to cisplatin observed previously.
Diederichs, Kay, Helliwell, John R, Kroon-Batenburg, Loes M. J, Schreurs, Antoine M. M, Tanley, Simon W. M   +4 more
core  

Systemic Therapy in Endometrial Cancer: Recent Advances. [PDF]

, 2013
Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well.
Bhise, R, Guru Prasad B, B, Kundargi, R, Lakshmaia, KC, Purohit, S, Shetty, R   +5 more
core   +1 more source

POU2F1 Promotes Chemoresistance in Colorectal Cancer Cells via Attenuates the MDR2 Degradation Mediated by PPP1R11 Lactylation

Advanced Science, EarlyView.
Schematic diagram of our study showing that highly expressed POU2F1 in colorectal cancer (CRC) can directly accelerate the cytosolic lactate export to decrease PPP1R11 lactylation at K59, thereby attenuating the E3 ligase enzyme activity and protein stability of PPP1R11, which inhibits the ubiquitination of MDR2 at K413 and K538 but increases the ...
Longzheng Xia, Jinguan Lin, Xianjie Jiang, Linda Oyang, Shiming Tan, Zongyao Ren, Qiu Peng, Qianjin Liao, Yujuan Zhou   +8 more
wiley   +1 more source

Afatinib use in recurrent epithelial ovarian carcinoma. [PDF]

, 2019
•Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies.•Targetable mutations may lead to new therapies in gynecologic cancer treatment.•Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 ...
Alvarez, Edwin A, Hanft, Wyatt J, Kennedy, Vanessa A, Shepherd-Littlejohn, Amanda L   +3 more
core   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Real‐World Treatment and Outcomes in Resectable Early‐Stage Non‐Small Cell Cancer: THASSOS‐INTL Australia Cohort

AGING MEDICINE, EarlyView.
Australia cohort of THASSOS‐INTL; non‐interventional, multicenter, retrospective study provides insights into treatment patterns and associated survival outcomes in patients with resectable stage I‐III NSCLC in the pre‐immunotherapy era. Neoadjuvant and adjuvant therapy was reported in < 10% and < 40% patients, respectively.
Pei Ding, Kevin Jasas, Victoria Bray, Abhijit Pal, Rebecca Moor   +4 more
wiley   +1 more source

Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer

Фармакоэкономика
Objective: to evaluate the pharmacoeconomic efficacy of “atezolizumab + bevacizumab + paclitaxel + carboplatin” drug combination compared to “pembrolizumab + pemetrexed + carboplatin” combination in adult patients with non-small cell lung cancer (NSCLC ...
S. К. Zyryanov, I. N. Dyakov
doaj   +1 more source

The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer [PDF]

, 2007
Annotated and edited transcript of a Witness Seminar held on 4 April 2006. Introduction by Professor Matti Aapro, Grenolier, Switzerland.First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2007.©The Trustee of the Wellcome ...
Christie, DA, Tansey, EM
core